- Location
pharmacokinetics
"-
Researchers at Columbia University Made a Significant Step Toward Visualizing Biomolecules
Mar 5, 2014Researchers at Columbia University have made a significant step toward visualizing small biomolecules inside living biological systems with minimum disturbance, a longstanding goal in the scientific community. In a study published March 2nd ...
-
Omeros Corporation Announced Positive Results From a Phase 2A Clinical Trial of OMS824
Feb 7, 2014Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic ...
-
Sorrento Therapeutics Announced a Definitive Agreement to Acquire Concortis Biosystems
Nov 18, 2013Sorrento Therapeutics, a clinical-stage biopharmaceutical company, has announced a definitive agreement to acquire US-based Concortis Biosystems. This acquisition provides Sorrento Therapeutics with a comprehensive technology platform for ...
-
The Study of Profil Institute's Early Phase Clinical Services
Apr 15, 2013Mercodia, a developer of immunoassays, has entered into a collaboration agreement with Profil Institute for Clinical Research. Under the alliance, Mercodia will offer its enzyme-linked immnosorbent assays (ELISA) as a component for Profil ...
Tags: Profil Institute, Mercodia, Clinical
-
Neurim Pharmaceuticals Has Announced Positive Results From a Phase II Clinical Study
Feb 20, 2013Neurim Pharmaceuticals has announced positive results from a phase II clinical study reviewing the efficacy and safety of piromelatine. The novel investigational multimodal sleep medicine has been developed for the treatment of patients ...
Tags: Neurim Pharmaceuticals, positive results, phase II clinical study
-
Critical Completed Second Clinical Trial on CP024 Intranasal Growth Hormone
Feb 19, 2013Critical Pharmaceuticals has completed second clinical trial on CP024 intranasal growth hormone. CP024 growth hormone nasal spray was safe and well tolerated in the study that administered six dose levels of CP024 in healthy subjects. ...
-
JULABO GmbH Announced The Recent Appointment of Michael Duchaussoy as Sales Manager
Feb 18, 2013JULABO GmbH is pleased to announce the recent appointment of Michael Duchaussoy as sales manager. His addition complements and strengthens the sales team providing services for customers particularly working in the area of temperature ...
Tags: JULABO, Sales Manager, GmbH
-
Hyperion Therapeutics Has Announced That It Has Gained Approval From FDA
Feb 5, 2013US-based biopharmaceutical company Hyperion Therapeutics has announced that it has gained approval from US Food and Drug Administration (FDA) for its RAVICTI (glycerol phenylbutyrate) liquid drug. RAVICTI used for treating Urea Cycle ...
Tags: FDA, drug, biopharmaceutical company
-
Theravance Has Commenced Phase 2b Study Desined to Evaluate Varying Doses of TD-4208
Dec 14, 2012Theravance has commenced Phase 2b study desined to evaluate varying doses of TD-4208 in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Theravance leveraged its multivalent approach of drug design to ...
Tags: drug, long-acting medicines, long-acting muscarinic antagonist
-
Horizon Pharma Has Commercially Launched Rayos Delayed Release Tablets in The US
Dec 10, 2012Horizon Pharma has commercially launched Rayos (prednisone) delayed release tablets in the US. Rayos is used to treat rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis (PsA), ankylosing spondylitis (AS), asthma ...
Tags: Horizon Pharma, Rayos, rheumatoid arthritis
-
Horizon Pharma RAYOS Tabletsreceived FDA Approval
Dec 7, 2012Horizon Pharma RAYOS (prednisone) delayed-release tablets have received the US Food and Drug Administration (FDA) approval. The approved drug is used to treat rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), psoriatic arthritis ...
Tags: Horizon Pharma RAYOS delayed-release tablets, rheumatoid arthritis, RA
-
Omeros Has Filed an Investigational New Drug Application with The FDA for OMS824
Dec 6, 2012Omeros has filed an investigational new drug application (IND) with the FDA for OMS824, the compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders. OMS824 targets and inhibits an enzyme ...
Tags: new drug application, FDA, OMS824
-
Inspiration Biopharmaceuticals Submitted Bla to The FDA
Dec 6, 2012Inspiration Biopharmaceuticals has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the approval of IB1001, used for the treatment and prevention of bleeding in individuals with hemophilia B. ...
Tags: FDA, IB1001, intravenous recombinant factor IX protein
-
Immunomedics' Proprietary DNL Technology Has Been Used to Create The New Anti-HIV Agents
Nov 29, 2012Sweden based Karolinska Institutet and Immunomedics scientists have collaborated to design and test new class of drugs that destroy the AIDS virus, HIV (Human Immunodeficiency Virus), which may also help in eliminating the virus completely. ...
Tags: Immunomedics, anti-HIV agents, virus
-
Pharmaron Has Signed a Multi-Year Agreement with AstraZeneca
Nov 29, 2012Pharmaron has signed a multi-year agreement with AstraZeneca to accelerate drug discovery by supporting the Medicines Units. Pursuant to the agreement, Pharmaron will offer discovery services in the areas of chemistry, drug metabolism and ...
Tags: drug discovery, medicines, chemistry, drug metabolism, pharmacokinetics
